NCT00144183View on ClinicalTrials.gov

A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

PHASE3CompletedINTERVENTIONAL

Enrollment

407

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

Acquired Immunodeficiency Syndrome

Interventions

DRUG

Nevirapine (NVP)

Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.

DRUG

Zidovudine (ZCV)

DRUG

3TC

Trial Locations (5)

2013

Boehringer Ingelheim Investigational Site, Soweto

2093

Boehringer Ingelheim Investigational Site, Johannesburg

4001

Boehringer Ingelheim Investigational Site, Durban

7505

Boehringer Ingelheim Investigational Site, Cape Town

0081

Boehringer Ingelheim Investigational Site, Attridgeville